The purpose of the protocol is to assess the efficacy and safety of BIM 23A760 on patient’s overall satisfaction in terms of symptom relief (diarrhoea and/or flushes) in patients with carcinoid syndrome after 24 weeks of treatment.
The purpose of the protocol is to assess the efficacy and safety of BIM 23A760 on patient’s overall satisfaction in terms of symptom relief (diarrhoea and/or flushes) in patients with carcinoid syndrome after 24 weeks of treatment.
The purpose of this study is to determine whether monthly injections of Somatuline Depot are effective and safe in controlling diarrhea and flushing by reducing the usage of short acting octreotide as rescue medication in patients with carcinoid syndrome. In countries where Somatuline Depot is not approved, patients well controlled at the end of the